ABOS Company Profile and Key Details

ABOS has shown mixed momentum, gaining 8.14% over the past week and -8.37% over the past quarter, though year-to-date performance is down -11.85%. Short-term trend indicators are bearishly aligned (SMA20 10.2%, SMA50 25.75%, SMA200 66.27%). The stock’s 14-day RSI is 64.0 (firm momentum), while the ATR of 0.22 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -7.21% below its high and over 230.96% above its low. Average 10-day trading volume of 247.29 thousand shares is below the 3-month average of 456.55 thousand, indicating normal recent market interest.

Acumen Pharmaceuticals, Inc. generated EPS of -$2.21 over the past year. Five-year average earnings growth is -54.87%. Wall Street analysts project EPS growth of 5.22% annually over the next five years. The latest quarter delivered EPS of -$0.33. The next quarter is forecast at -$0.45. Next year's EPS is expected at -$28.57. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 5 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $9.00 to $7.00. The high target offers 270.37% upside. The low target suggests 188.07% downside. The mean target is $8.00. This offers 229.22% upside. Acumen Pharmaceuticals, Inc. earnings surprise history is a mixed track record. The quarter that ended May 12, 2026, missed forecasts by -18.07%. The prior quarter beat by -18.0%. Over the last six quarters, Apple has recorded several small beats. These include 31.91% in March 27, 2025.

Acumen Pharmaceuticals, Inc. has 72.23 million shares outstanding. The public float is 36.96 million shares, elevated short interest at 5.59% of float. This equals 2.81 million shares. The short ratio is 3.97 days. Institutional investors hold 69.36% of the float. Insiders own 6.8%. RA CAPITAL MANAGEMENT, L.P. holds 13.04 million shares, Hardie Robert D. has 3.95 million shares and Sands Capital Ventures Discovery Fund III, L.P. has 3.42 million shares. Over the past six months, insider transactions show net selling. They sold 50.20 thousand shares across 6 transactions.

Acumen Pharmaceuticals, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.37. This means the shares are trading above this model’s fair value.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) closed at $2.43 USD, losing -$0.01 (-0.41%) from the previous close of $2.44. The stock is currently mid-range between its 52-week high and low $1.19 and $3.60. With a market capitalization of about $175.51 million, Acumen Pharmaceuticals, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.33). Key stats such as the average daily volume over the past year has been around 454.63 thousand shares, volume is running light vs its 52-week average. Headquartered in Newton, MA, Acumen Pharmaceuticals, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Daniel J. O'Connell, the company employs approximately 61 people and listed since July 01, 2021. Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease.

Acumen Pharmaceuticals, Inc. trades at a P/E ratio of -1.29, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.74 suggesting the stock is closer to book value. The P/FCF stands at -1.65, also above market averages.

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares are down -11.85% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Acumen Pharmaceuticals, Inc. trading at a premium to the broader market with a P/E of -1.29. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $12.12, suggesting 398.77% upside. Our AI forecast model points to short-term weakness (-3.7% over two weeks), a medium-term fall (-20.99% over three months), and a longer-term gain (62.96% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Acumen Pharmaceuticals, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.7%, with price expected at $2.34 by August 24, 2026, within a range of $2.14 to $2.55 3-Month Outlook: Projected fall of -20.99%, reaching $1.92 by November 06, 2026, with a range of $1.78 to $2.05. 1-Year Outlook: Projected gain of 62.96%, with price at $3.96 by August 10, 2027, within a range of $0.00 to $3.25.